Search
Descriptor English: Auranofin
Descriptor Spanish: Auranofina
Descriptor auranofina
Scope note: Agente crisoterapéutico oral para el tratamiento de la artritis reumatoide. Se desconoce su mecanismo de acción exacto, pero se cree que atúa por medio de mecanismos inmunológicos y alteración de la actividad de enzimas lisosómicas. Su eficacia es ligeramente menor que la de las sales de oro inyectadas, pero se tolera mejor, y los efectos secundarios que se producen son potencialmente menos graves.
Descriptor Portuguese: Auranofina
Descriptor French: Auranofine
Entry term(s): Crisinor
Ridaura
Ridauran
SK&F 39162
SK&F D 39162
SK&F-39162
SK&F39162
Tree number(s): D02.691.675.249.150
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D001310
Scope note: An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antirheumatic Agents
Registry Number: 3H04W2810V
CAS Type 1 Name: Gold, (1-thio-beta-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-
Previous Indexing: Gold (1966-1974)
Gold Thioglucose/analogs & derivatives (1975-1986)
Public MeSH Note: 87
History Note: 87
DeCS ID: 29367
Unique ID: D001310
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1987/01/01
Date of Entry: 1986/06/16
Revision Date: 2016/07/05
Auranofin - Preferred
Concept UI M0001971
Scope note An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
Preferred term Auranofin
Ridaura - Narrower
Concept UI M0001972
Preferred term Ridaura
SK&F D 39162 - Narrower
Concept UI M0352110
Preferred term SK&F D 39162
Entry term(s) SK&F 39162
SK&F-39162
SK&F39162
Crisinor - Narrower
Concept UI M0440875
Preferred term Crisinor
Ridauran - Narrower
Concept UI M0440874
Preferred term Ridauran



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey